Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Genovese

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Biomedical Materials Research. Part A|March 14, 2003
Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particlesStuart Goodman, Michael Trindade, Ting Ma, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
Modern Rheumatology|November 7, 2024
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Modern Rheumatology|August 3, 2022
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
The Journal of Rheumatology|August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trialJoel Kremer, Mark Genovese, Grant W Cannon, et al.
Arthritis and Rheumatism|October 31, 2009
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trialEva C Koffeman, Mark Genovese, Diane Amox, et al.
Annals of the Rheumatic Diseases|November 8, 2015
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritisTheresa Wampler Muskardin, Priyanka Vashisht, Jessica M Dorschner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 8, 2021
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisLiana Fraenkel, Joan M Bathon, Bryant R England, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Biomedical Materials Research. Part A|March 14, 2003
Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particlesStuart Goodman, Michael Trindade, Ting Ma, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
Modern Rheumatology|November 7, 2024
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Modern Rheumatology|August 3, 2022
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
The Journal of Rheumatology|August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trialJoel Kremer, Mark Genovese, Grant W Cannon, et al.
Arthritis and Rheumatism|October 31, 2009
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trialEva C Koffeman, Mark Genovese, Diane Amox, et al.
Annals of the Rheumatic Diseases|November 8, 2015
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritisTheresa Wampler Muskardin, Priyanka Vashisht, Jessica M Dorschner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 8, 2021
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisLiana Fraenkel, Joan M Bathon, Bryant R England, et al.
Pageof 4